Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hemophilia B Gene Therapy - Spark

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Spark Therapeutics, LLC
Sponsor:
Collaborators:
Children's Hospital of Philadelphia
University of Pittsburgh
Royal Prince Alfred Hospital, Sydney, Australia
St. James's Hospital, Ireland
Information provided by (Responsible Party):
Spark Therapeutics, LLC
ClinicalTrials.gov Identifier:
NCT01620801
First received: June 12, 2012
Last updated: October 31, 2014
Last verified: October 2014

June 12, 2012
October 31, 2014
October 2012
October 2019   (final data collection date for primary outcome measure)
Number of subjects with adverse events related to investigational product [ Time Frame: One year (with 15-year follow-up) ] [ Designated as safety issue: Yes ]
Physical exams; clinical labs, including evaluation of FIX inhibitor; and adverse event reporting.
Number of subjects with adverse events related to investigational product [ Time Frame: One year ] [ Designated as safety issue: Yes ]
Physical exams; clinical labs, including evaluation of FIX inhibitor; and adverse event reporting.
Complete list of historical versions of study NCT01620801 on ClinicalTrials.gov Archive Site
Circulating plasma factor IX levels [ Time Frame: One year (with 15-year follow-up) ] [ Designated as safety issue: Yes ]
Factor IX activity and antigen; PT; and aPTT.
Same as current
Not Provided
Not Provided
 
Hemophilia B Gene Therapy - Spark
A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX

Hemophilia B is a bleeding disease in males due to very low levels of coagulation factor IX (FIX) in the blood. The current treatment is intravenous injection of FIX clotting factor concentrates, in response to bleeding. This study will focus on the severe, most common type of hemophilia B. This study plans to use a virus called adeno-associated virus (AAV), which in nature causes no disease, and can be engineered to deliver the human FIX gene (AAV8-hFIX19 vector) to liver cells, where FIX is normally made. This study will use the AAV8-hFIX19 vector.

Hemophilia B is a bleeding disease in males due to very low levels of coagulation factor IX (FIX) in the blood. The major effect on health is joint disease caused by repeated bleeds into joints like the knee, hip, ankles and elbows. Rarely, the disease causes death due to bleeding into the brain or other important organs. The current treatment is intravenous injection of FIX clotting factor concentrates, in response to bleeding. This study will focus on the severe, most common type of hemophilia B.

This study plans to use a virus called adeno-associated virus (AAV), which in nature causes no disease, and can be engineered to deliver the human FIX gene (AAV8-hFIX19 vector) to liver cells, where FIX is normally made. Medical researchers in the United States and England have recently used an AAV vector similar to the one planned for this study, and found that after a single intravenous injection of the vector, blood levels of FIX reached levels greater than 1%, high enough to change the course of disease from severe to moderate. This means that the need to take FIX clotting factor concentrates has decreased, or even stopped. While these are important results, it needs to be noted that two of the six subjects who received the vector at higher doses developed inflammation of the liver. These subjects were treated with a steroid medication called Prednisolone, which is commonly used for serious types of inflammation. Prednisolone seemed to decrease the liver inflammation, as measured by a decrease in blood levels of elevated liver enzymes, and stability of FIX levels at greater than 1% of normal.

This study will use the AAV8-hFIX19 vector. The vector will be injected once into a peripheral vein of each subject, while the subject is in the hospital. If everything is fine, the subject will be discharged from the hospital the next day. Three doses of vector (low, middle, and high) will be tested in up to 15 different subjects, depending on safety outcome (as determined by blood and urine tests) and results of FIX levels. If some subjects develop liver inflammation, a short, tapering course of corticosteroids will be used.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Hemophilia B
Biological: AAV8-hFIX19
One-time IV vector administration.
  • Experimental: Low dose
    AAV8-hFIX19
    Intervention: Biological: AAV8-hFIX19
  • Experimental: Middle dose
    AAV8-hFIX19
    Intervention: Biological: AAV8-hFIX19
  • Experimental: High dose
    AAV8-hFIX19
    Intervention: Biological: AAV8-hFIX19
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
15
October 2029
October 2019   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Willingness to adhere to the clinical protocol and 15-year long-term follow-up as evidenced by written informed consent
  • Adult males at least 18 years of age
  • A. Severe FIX deficiency (<1% normal circulating FIX) or B. Moderately severe FIX deficiency (1-2% normal circulating FIX, inclusive) and a severe bleeding phenotype as defined by at least one of the following: i. On prophylaxis for a history of bleeding or ii. On demand therapy with a current or past history of frequent bleeding [4 or more bleeding episodes in the last 12 months or chronic hemophilic arthropathy (pain, joint destruction, and loss of range of motion) in one or more joints]
  • No history of inhibitor against FIX
  • No history of an allergic reaction or anaphylaxis to FIX products
  • Greater than 20 exposure days of treatment with FIX protein
  • Anti-AAV8 neutralizing titer measured at < 1:5
  • Acceptable laboratory values: hemoglobin ≥ 11% gm; WBC ≥ 3,500/μL; platelets ≥ 100,000/μL; AST, ALT, alkaline phosphatase ≤ 2x ULN; bilirubin ≤ 1.2 gm/dL; and creatinine ≤ 1.5 gm/dL
  • Subject agrees to use barrier contraception until at least two consecutive semen samples after vector administration are negative for vector sequences (may be for up to several months)

Exclusion Criteria:

  • Subjects with active hepatitis B or C, and HBsAg or HCV RNA viral load positivity, respectively. Negative viral assays in two samples, collected at least six months apart, will be required to be considered negative. Both natural clearers and those who have cleared HCV on antiviral therapy are eligible.
  • Subjects currently on antiviral therapy for hepatitis B or C
  • Subjects with significant underlying liver disease, as defined by presence of portal hypertension, splenomegaly, varices, ascites, edema, gastrointestinal bleeding, encephalopathy, reduction below normal limits of serum albumin, or prior liver biopsy demonstrating significant fibrosis, specifically ≥ Metavir 3 fibrosis
  • Subjects with serological evidence of HIV who have CD4 counts ≤ 200/mm3. Subjects who are HIV-positive and stable, with an adequate CD4 count (> 200/mm3) and undetectable viral load (< 50 gc/mL) measured twice in the six months prior to enrollment, on an antiretroviral drug regimen are eligible to enroll.
  • History of inhibitor against FIX
  • Anti-AAV8 antibody titers ≥ 1:5
  • History of chronic infection or other chronic diseases which the investigators consider to constitute an unacceptable risk
  • Subjects who have participated in a previous gene therapy research trial within one year of enrollment
  • Subjects who have participated in a clinical study with an investigational drug within six months of enrollment
  • Any other condition that would not allow the potential subject to complete follow-up examinations during the course of the study or, in the opinion of the investigator, makes the potential subject unsuitable for the study
Male
18 Years and older
No
Contact: Sarah Hahn, RN (267) 425-0133 hahnsj@email.chop.edu
United States,   Australia
 
NCT01620801
AAV8-hFIX19-101
Yes
Spark Therapeutics, LLC
Spark Therapeutics, LLC
  • Children's Hospital of Philadelphia
  • University of Pittsburgh
  • Royal Prince Alfred Hospital, Sydney, Australia
  • St. James's Hospital, Ireland
Principal Investigator: Margaret V Ragni, MD University of Pittsburgh
Spark Therapeutics, LLC
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP